Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate

BACKGROUND AND OBJECTIVES: Palbociclib is a cyclin-dependent kinase 4/6 inhibitor that is approved in the United States for the treatment of hormone receptor‒positive (HR+)/human epidermal growth factor receptor‒2 negative (HER2−) advanced breast cancer (ABC). The objectives of this expanded access...

Descripción completa

Detalles Bibliográficos
Autores principales: Fein, Luis, Lazaretti, Nicolas, Chuken, Yamil López, Benfield, J. Rogelio González Ramírez, Mano, Max S., Lobaton, Jose, Korbenfeld, Ernesto, Damian, Fernanda, Lu, Dongrui R., Mori, Ave, Patyna, Shem J., Franco, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514159/
https://www.ncbi.nlm.nih.gov/pubmed/37594640
http://dx.doi.org/10.1007/s40261-023-01294-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514159/
https://www.ncbi.nlm.nih.gov/pubmed/37594640
http://dx.doi.org/10.1007/s40261-023-01294-3

Ejemplares similares